184878-99-7

Upstream product

• 99-89-8 4-Isopropylphenol 
• 105-39-5 chloroacetic acid ethyl ester 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 858612-91-6 3-(4-Chloro-phenyl)-2-(4-isopropyl-phenoxy)-propionic acid ethyl ester 
• 184879-49-0 2-(4-Chloro-benzyl)-2-(4-isopropyl-phenoxy)-succinic acid 4-benzyl ester 1-ethyl ester 
• 184879-01-4 2-[1-(4-Isopropyl-phenoxy)-2-(2-trifluoromethyl-phenyl)-ethyl]-4,4-dimethyl-4,5-dihydro-oxazole 
• 184879-45-6 2-(2-Chloromethyl-4-isopropyl-phenoxy)-3-(4-chloro-phenyl)-propionic acid ethyl ester 
• 184879-50-3 2-(4-Chloro-benzyl)-2-(4-isopropyl-phenoxy)-succinic acid 1-ethyl ester 
• 184879-52-5 2-(4-Chloro-benzyl)-4-hydroxy-6-isopropyl-chroman-2-carboxylic acid ethyl ester 
• 184879-51-4 2-(4-Chloro-benzyl)-6-isopropyl-4-oxo-chroman-2-carboxylic acid ethyl ester 
• 184879-46-7 2-(4-Chloro-benzyl)-5-isopropyl-2,3-dihydro-benzofuran-2-carboxylic acid ethyl ester 
• 1026600-60-1 2-[2-(3-Fluoro-phenyl)-1-(4-isopropyl-phenoxy)-ethyl]-4,4-dimethyl-4,5-dihydro-oxazole 
• 850908-51-9 2-(4-Chloro-benzyl)-6-isopropyl-chroman-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, inflammatory disease of the joints, neuropathies, HIV-related neuropathy, nerve injury, neurodegeneration, stroke, urinary bladder hypersensitivity including urinary incontinence, cystitis, stomach duodenal ulcer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), fecal urgency, gastro-esophageal reflux disease (GERD), Crohn's disease, asthma, chronic obstructive pulmonary disease, cough, neurotic/allergic/inflammatory skin disease, psoriasis, pruritus, prurigo, irritation of skin, eye or mucous membrane, hyperacusis, tinnitus, vestibular hypersensitivity, episodic vertigo, cardiac diseases such as myocardial ischemia, hair growth-related disorders such as effluvium, alopecia, rhinitis, and pancreatitis.

Glucose transport-enhancing and hypoglycemic activity of 2-methyl-2- phenoxy-3-phenylpropanoic acids

A series of 2-phenoxy-3-phenylpropanoic acids has been prepared which contains many potent hypoglycemic agents as demonstrated by assessing glucose lowering in ob/ob mice. Some compounds (32, 33, 59) normalize plasma glucose in this diabetic model at doses of approximately 1 mg/kg. The mechanism of action of these drugs may involve enhanced glucose transport, especially in fat cells, but the compounds do not stimulate GLUT4 translocation and do not increase the levels of GLUT1 or GLUT4 in vivo. Thus, these compounds may enhance the intrinsic activity of the glucose transporter GLUT1 or GLUT4. Some compounds also modestly decrease hepatocyte gluconeogenesis in vitro, but this is not likely to be a major contributor to the hypoglycemic effect observed in vivo. Likewise, a modest decrease in food consumption observed with some of these compounds was shown by a pair-feeding experiment not to be the primary cause of the hypoglycemia observed.